Partner Content Partner Content Registration opens for SMi’s leading Pain Therapeutics Confe... Registration opens for Pain Therapeutics
News Pain Therapeutics' opioid drug fails to gain FDA approval The US regulator has rejected Pain Therapeutics' abuse-deterrent opioid painkiller drug, Remoxy, for the fourth time.
Partner Content Partner Content Pain Therapeutics conference is taking place in London next ... SMi Group reports: To reserve last available seats at the Pain Therapeutics Conference, head on to the event website http://www.pain-therap
Partner Content Partner Content Great time for pain research: exclusive interviews with indu... SMi Group reports: Ahead of 18th annual Pain Therapeutics Conference (London, 21 - 22 May) SMi Group have caught up with Neil S
Partner Content Partner Content Explore innovative approaches and novel targets in analgesic... The opioid crisis has cost the economy $1 trillion since 2001 in the USA alone, and the prospect does not look like it will get better any time soon.
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
